I2I
BIO icon

Insight 2811 Inc’s Bio-Rad Laboratories Class A BIO Stock Holding History

Insight 2811 Inc’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,100
Closed -$219K – 79
2017
Q1 		$219K Buy
+1,100
New +$212K 0.17% 73

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Insight 2811 Inc's BIO Position: Q2 2017 in Review

Insight 2811 Inc sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2017, closing a stake of 1,100 shares — an estimated $219K sold.

Insight 2811 Inc first reported a position in BIO in Q1 2017 and held it in 1 quarter. The position peaked at $219K in Q1 2017. 276 funds tracked by Wall St. Rank hold BIO as of Q2 2017.

  • Insight 2811 Inc reported no remaining Bio-Rad Laboratories Class A position as of Q2 2017 after selling out during the quarter.
  • Insight 2811 Inc sold 1,100 Bio-Rad Laboratories Class A shares in Q2 2017, an estimated $219K.
  • Insight 2811 Inc first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 1 quarter.
  • Insight 2811 Inc's Bio-Rad Laboratories Class A position peaked at $219K in Q1 2017.
  • 276 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2017.

Based on Insight 2811 Inc's 13F filing for Q2 2017, filed 1 Aug 2017.